Scope and methodology
Oral anticoagulants are used to prevent and treat a wide range of thromboembolic diseases. Currently available oral anticoagulants include the vitamin K antagonists (VKAs), such as warfarin. VKAs reduce the synthesis of functional vitamin K-dependent factors (factor II, FVII, FIX, FX, as well as protein C and protein S) by interfering with the vitamin K redox cycle. The newer oral anticoagulants (dabigatran, rivaroxaban, apixaban, edoxaban, and betrixaban) each directly inhibit an activated clotting factor, either FIIa or FXa. Their pharmacokinetic and pharmacodynamic properties are more predictable than those of the VKAs, so routine monitoring of the anticoagulant effect is not required [1] .
Various terms have been used to describe the 'new' class of oral anticoagulants, although they are not so new or novel any more. Terms that are commonly encountered in the medical literature include: novel/new oral anticoagulants (NOACs), direct oral anticoagulants (DOACs), and target-specific oral anticoagulants (TSOACs). However, the use of multiple terms and abbreviations can lead to fragmentation of the medical literature, and confusion among providers and patients. The term NOAC has been used the longest, and, recently, some have argued for use of the term 'non-VKA oral antagonists' (NOACs), to take advantage of the commonly used abbreviation without using the terms novel and new [2] . However, identifying a class of drugs by what they are not is scientifically unappealing. Perhaps more importantly, there is at least one reported account where the term NOAC written in the medical record was interpreted as meaning 'No AntiCoagulation,' potentially resulting in the patient not receiving the critical therapy that was intended [3] .
There is a clear need to reach a consensus on the nomenclature of oral anticoagulants, and several experts have called for consensus around the nomenclature for oral anticoagulants [2, [4] [5] [6] [7] .
We aimed to develop guidance from the Control of Anticoagulation SSC of ISTH on the most appropriate abbreviation for the newer/novel/target-specific/direct-acting oral anticoagulants by seeking the opinions of thrombosis and anticoagulation thought leaders.
We administered a web-based survey (Data S1) to the leaders (primarily board members) of 16 thrombosis, hemostasis, anticoagulation and vascular medicine societies from seven different countries in North America and Europe (150 recipients in total) in September 2014. These societies were selected on the basis of their clinical interests in vascular medicine, thrombosis, or anticoagulation. All medical officers of each society whose contact information was available were invited to participate in the survey. Two reminders were sent to each participant, and those who participated were not compensated. Of the 150 recipients, 77 (51%) completed the survey. In this survey, we asked about their opinion regarding: (i) the need for consensus around oral anticoagulation nomenclature; (ii) concerns about the safety of using the term NOAC; and (iii) their preferred term to describe this new class of oral anticoagulants. On the basis of these survey results, the following guidance statements were formulated.
The vast majority (89.6%) of the respondents felt that there was a need to reach a consensus on terminology. 
Concerns with the term NOAC
Anticoagulants are known to reduce the morbidity and mortality associated with a number of thrombotic conditions. In each of these conditions, lack of anticoagulant therapy can have dramatic effects on patient outcomes. In some reports, use of the term NOAC has been misinterpreted as 'No AntiCoagulation', which may lead to the inadvertent omission of important anticoagulant therapy for a patient with a thrombotic disorder [3] . In our survey, only 41 (54.7%) respondents agreed that the term NOAC had safety implications that should limit its use. This is not surprising, because many physicians would not necessarily agree that many of the terms considered to be unsafe by the Institute for Safe Medical Practices are really unsafe [8] . Some have argued that the term NOAC should be used and evolve, and that the 'N' should represent Non-VKA antagonist instead of new/ novel, because this terminology is well established in the medical literature [5] . However, many experts also feel that, ideally, a class of medications should be defined by a positive characteristic or general mode of action, rather than by a negative property that is lacking.
Despite the frequent adoption of NOAC in the medical literature, and calls by some thrombosis and anticoagulation leaders to use non-vitamin K oral anticoagulant (NOAC), we feel that the potential safety implications and lack of pharmacologic specificity of this abbreviation should prevent its widespread use. Additionally, although some have encouraged the use of non-VKA OAC as the best term, we feel that this is both cumbersome and too easily abbreviated as NOAC by clinicians and in the literature, with the safety implications noted above.
Recommendation statements for consensus around oral anticoagulation nomenclature and harm with NOAC Evidence for the use of DOAC Unlike VKAs, the direct oral anticoagulants target one specific factor (currently either FXa or FIIa). Specifically, dabigatran inhibits thrombin (FIIa), whereas rivaroxaban, apixaban, edoxaban and betrixaban all inhibit FXa. Use of the term 'direct' adequately distinguishes this class of medications from the VKAs, and allows each of these medications to be discussed on the basis of their similar (but not exactly the same) clinical profiles. In our survey, DOAC received the most votes (45, 58.4%) as an acceptable term for this class of medications. When respondents were asked to pick the single best term, however, no single choice dominated. Twenty-three (29.9%) respondents selected DOAC, 22 (28.6%) selected NOAC (non-VKA oral anticoagulant), and 18 (23.4%) selected TSOAC. With low support for TSOAC in this survey of thrombosis and anticoagulation experts, this term was not felt to be the best single choice for routine use. Given the potential safety limitations associated with the use of NOAC and the relative specificity of pharmacologic action, DOAC is a reasonable choice. DOAC is also used widely in the published literature, making it a very reasonable selection [6, [9] [10] [11] . Many respondents commented that the best descriptive term is one that describes the mechanism of action, such as direct thrombin inhibitor and direct FXa inhibitor. However, given the many similarities between the oral agents of these two groups, it seems reasonable to describe them together for the majority of clinical scenarios. Nevertheless, they can be distinguished by their mechanism of action in situations where it is clinically relevant (e.g. selecting appropriate coagulation laboratory testing and for potential medication strategies).
Recommendation statement for the use of DOAC 1 We suggest using the term 'direct oral anticoagulant' (DOAC) to reference the class of oral anticoagulants that directly inhibit a single target and have similar clinical properties (e.g. dabigatran, rivaroxaban, apixaban, edoxaban, and betrixaban). 2 We suggest that a drug's specific mechanism of action (e.g. direct FXa inhibitor or direct thrombin inhibitor) should be used when it is clinically important to distinguish between the various DOAC medications. 
Society endorsements

